My watch list  

Exiqon A/S wins prestigious Ernst & Young Entrepreneur of the Year Award


Exiqon A/S announced that it has won the Ernst & Young Entrepreneur Of The Year award in the category Biotech 2005. The prestigious award is created to identify and acknowledge the most successful and entrepreneurial Danish companies.

A minimum growth of 15% in sales as well as growth in staff is among the key nomination criteria. An impressive turnaround of the company in just 2 years, a successful business strategy and break-through research results were some of the points emphasized by the jury when Exiqon was named the best biotech company in Ernst & Young Entrepreneur of the Year competition.

Facts, background information, dossiers
  • Exiqon
  • Ernst & Young
More about Exiqon
  • News

    QIAGEN to submit conditional voluntary takeover offer for shares of Exiqon A/S

    QIAGEN N.V. announced that it has decided to submit a conditional voluntary takeover offer to the shareholders of Exiqon A/S to purchase all shares in Exiqon. The acquisition is expected to expand QIAGEN’s leadership position in Sample to Insight solutions for RNA analysis. This announcemen ... more

    Michael Kallelis to manage Exiqon's new us facility

    Exiqon A/S announced the appointment of Michael Kallelis as President and General Manager of Exiqon's new US operations. Mr. Kallelis will have the overall responsibility for launching and operating Exiqon's US office to be located in the Boston area. A key focus of the new facility will be ... more

    U.S. Genomics Licenses Locked Nucleic Acid (LNA(TM)) Chemistries from Exiqon

    Woburn and Copenhagen. U.S. Genomics and Exiqon have entered into a worldwide license agreement to incorporate Exiqon's Locked Nucleic Acid (LNA(TM)) chemistries into reagent kits for the U.S. Genomics Trilogy(TM) platform. Introduced into the market early last month, the Trilogy(TM) platfo ... more

  • Companies

    Exiqon A/S

    Enabling life science researchers to make groundbreaking discoveries Exiqon combines leading-edge scientific expertise in gene expression with our proprietary LNA™ technology. Our products, services and scientific staff enable life science researchers to make groundbreaking discoveries. ... more

More about Ernst & Young
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE